Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment

Cancer Letters

Volumn 298, Issue 1, 2010, Pages 34-49

  Wang, Pei ^a   Zhao, Xin Han ^a   Wang, Zhi Yu ^a   Meng, Min ^a   Li, Xu ^a   Ning, Qian ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biocompatibility; Gene delivery; ODNs; Polyamidoamine dendrimer; VEGF

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BOVINE SERUM ALBUMIN; DENDRIMER; POLYAMIDOAMINE; RESTRICTION ENDONUCLEASE; VASCULOTROPIN; NANOPARTICLE; NYLON; PAMAM-G4; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOAVAILABILITY; BIOCOMPATIBILITY; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ERYTHROCYTE SHAPE; FEMALE; GENE DELIVERY SYSTEM; GENE VECTOR; HEMOLYSIS; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ERYTHROCYTE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; STATIC ELECTRICITY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DENDRIMERS; ERYTHROCYTES; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; NYLONS; SERUM ALBUMIN, BOVINE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS; GENETIC THERAPY;

MUS;

EID: 77956937217     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.06.001     Document Type: Article

References (29)

1. Eichman J.D., Bielinska A.U., Kukowska-Latallo J.F., Baker J.R. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Res. Focus 2003, 3:232-245.
2. Dennig J., Duncan E. Gene transfer into eukaryotic cells using activated polyamidoamine dendrimers. Rev. Mol. Biotechnol. 2002, 90:339-347.
3. Choi J.S., Nam K., Park J.Y., Kim J.B., Lee J.K., Park J.S. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine. J. Controlled Release 2004, 99:445-456.
4. Navarro Gemma, de ILarduya Conchita Tros Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo. Nanomedicine 2009, 5:287-297.
5. Zhang X.Q., Wang X.L., Huang S.W., Zhuo R.X., Liu Z.L., Mao H.Q. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core. Biomacromolecules 2005, 6:341-350.
6. Bajpai A.K., Saini R. Preparation and characterization of novel physically cross-linked hydrogels composed of poly (vinyl alcohol) and amine-terminated polyamidoamine dendrimers. Macromol. Biosci. 2004, 4:71-75.
7. Hussain M., Shchepinov M.S., Sohail M., Benter Ibrahim F., Hollins Andrew J., Southern Edwin M., Saghir A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J Controlled Release 2004, 99:139-155.
8. Mo Z.L., Liu Y.Z., Chen H., Li H.J., Sun Y.L. Preparation and molecular dynamics simulation of Sm/PAMAM nano-composite. Rare Metal Mater. Eng. 2007, 36:32-36.
9. Shcharbin D., Janicka M., Wasiak M., Palecz B., Przybyszewska M., Zaborski M., Bryszewska M. Serum albumins have five sites for binding of cationic dedrimers. Biochim. Biophys. Acta 2007, 1774:946-961.
10. Klajnert B., Stanislawska L., Bryszewska M., Palecz B. Interaction between PAMAM dendrimers and bovine serum albumin. Biochim. Biophys. Acta 2003, 1648:115-126.
11. Guo C.Y., Wang H., Lin Y.H., Cai O.L. Application of starburst(TM) PAMAM dendrimers as DNA carriers in vitro. Prog. Biochem. 2004, 31:804-811.
12. Shoji Y., Nakashima H. Current status of delivery systems to improve target efficiency of oligonucleotides. Curr. Pharm. Des. 2004, 10:785-796.
13. Domanski D.M., Klajnert B., Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004, 63:189-191.
14. Jevprasesphanta R., Pennya J., Jalala R., Attwooda D., McKeownb N.B., D'Emanuele A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 2003, 252:263-266.
15. Kolhatkar R.B., Kitchens K.M., Swaan P.W., Ghandehari H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug. Chem. 2007, 18:2054-2060.
16. Maszewska M., Leclaire J., Cieslak M., Nawrot B., Okruszek A., Caminade Am., Majoral Jp. Water-soluble polycationic dendrimers with a phosphoramidothioate backbone: preliminary studies of cytotoxicity and oligonucleotide/plasmid delivery in human cell culture. Oligonucleotides 2003, 13:193-205.
17. Pisala Dipak S., Yellepeddia Venkata K., Kumara Ajay, Kaushikb Radhey S., Hildrethc Michael B., Guana Xiangming, Palakurthia Srinath Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across caco-2 cell monolayers. Int. J. Pharm. 2008, 350:113-121.
18. Theoharis Stefanos, Krueger Ute, Tan Peng Hong, Haskard Dorian O., Weber Martin, George Andrew J.T. Targeting gene delivery to activated vascular endothelium using anti-E/P-selectin antibody linked to PAMAM dendrimers. J. Immuno Meth. 2009, 343:79-90.
19. Parkhouse Susan M., Garnett Martin C., Chan Weng C. Targeting of polyamidoamine-DNA nanoparticles using the Staudinger ligation: attachment of an RGD motif either before or after complexation. Bioorg. Med. Chem. 2008, 16:6641-6650.
20. Kobayashi H., Brechbiel M.W. Nano-sized MRI contrast agents with dendrimer cores. Adv. Drug Deliv. Rev. 2005, 57:2271-2286.
21. Nam Hye Yeong, Hahn Hwa Jeong, Nam Kihoon, Choi Woo-Hyung, Jeong Yunseong, Kim Dong-Eun, Park Jong-Sang Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int. J. Pharm. 2008, 363:199-205.
22. Perez A.P., Romero E.L., Morilla M.J. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents. Int. J. Pharm. 2009, 380:189-200.
23. Kitchens Kelly M., El-Sayed Mohamed E.H., Ghandehari Hamidreza Trans epithelial and endothelial transport of poly(amidoamine) dendrimers. Adv. Drug Deliv. Rev. 2005, 57:2163-2176.
24. Pan Bifeng, Cui Daxiang, Sheng Yuan, Ozkan Cengiz, Gao Feng, He Rong, Li Qing, Xu Ping, Huang Tuo Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007, 67:8156-8163.
25. Berna M., Dalzopo D., Pasut G., et al. Novel monodisperse PEG dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake. Biomacromolecules 2006, 7:146-153.
26. Eichman Jonathan D., Bielinska Anna U., Kukowska-Latallo Jolanta F., James Baker R. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm. Sci. Technol. Today 2000, 3:232-245.
27. Tsutsumi T., Hirayama F., Uekama K., et al. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Controlled Release 2007, 119:349-359.
28. Jevprasesphant R., Penny J., Jalal R. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 2003, 252:263-266.
29. Yi Liu, Bryantsev Vyacheslav S., Diallo Mamadou S., Goddard William A. PAMAM dendrimers undergo pH responsive conformational changes without swelling. J. Am. Chem. Soc. 2009, 131:2798-2799.